research centers


Search results: Found 17

Listing 1 - 10 of 17 << page
of 2
>>
Sort by

Article
Outcome of Induction Therapy in Adult Patients with Acute Myeloid Leukemia

Author: Alaadin Sahham Naji
Journal: Iraqi Academic Scientific Journal المجلة العراقية للاختصاصات الطبية ISSN: 16088360 Year: 2014 Volume: 13 Issue: 3 Pages: 313-319
Publisher: The Iraqi Borad for Medical Specialization المجلس العراقي للاختصاصات الطبية

Loading...
Loading...
Abstract

ABSTRACT:BACKGROUND: Treatment of patients with newly diagnosed acute myeloid leukemia (AML) has improved during the past decades due to the intensification of induction and post remission chemotherapies and due to the incorporation of autologous and allogeneic transplantation procedures. Untreated acute leukemia is a uniformly fatal disease with a median survival time shorter than 3 months. OBJECTIVE:To evaluate the outcome of induction and complications post induction in adult patients with Acute Myeloid Leukemia(AML) in Baghdad Teaching HospitalPATIENTS AND METHODS: A total of 47 patients diagnosed as de novo AML who had been admitted within twelve months from January till December 2012 in hematology unit of Baghdad Teaching Hospital were included. Treatment of the 47 eligible patients for remission induction with standard intensive treatment course consisted of the combination with standard-dose cytosine arabinoside 100 mg/m2/d continuous infusion on days 1-7, with of doxorubicin in a dose of 30mg/m2 over half an hour infusion on day 1-3.Response to therapy was assessed for complete remission or persistence of leukemic cell post induction. Pattern and severity of infections and their relationship with granulocytopenia. were analyzed.RESULTS:The patients had a mean age of of 36.7 years ranged from 14 to 72 years. Performance status in 15 patients was 0 or I while the majority (43) patients was with PS of II-IV at diagnosis according to WHO/ECOG performance status scale. Duration between symptoms of AML prior diagnosis till suspicion of a diagnosis of AML at a referring hospital and confirmation of the diagnosis at our institute have been assessed with( mean +SD) duration 32±22.1days.of the 47 patients 22(47%) achieved complete remission post first induction (CR1)and further 5(11%) patients have CR2(after second remission) and 20(42%) was refractory to treatment. Focus of infection during marrow hypoplasia have been identified in 26(59%) patients.CONCLUSION: Based on the current data ,the remission rate was nearly comparable to the results with other reports . Intensification of anthracyclins and identification of cytogenetic and other independent prognostic relevance are needed to obtain better results.


Article
Plasma IL-10 Concentration and Its Role in the Pathogenesis of Acute Myeloid Leukemia: a Prospective Study

Author: Kifah Jabbar Alyaqubi1, Azhar Jasim AL-kaabi2, Siham Jasim AL-kaabi3
Journal: Iraqi Journal of Biotechnology المجلة العراقية للتقانات الحياتية ISSN: 18154794 Year: 2016 Volume: 15 Issue: 1 Pages: 61-67
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Many suggestions support that cytokines have pathogenesis role of acute myeloid leukemia (AML) patients and that may be related with disease progression and patient survival. But their prognostic significance in this disease is unknown. The study aimed to estimate the plasma level of IL-10 before and after treatment in patients with AML. Plasma concentrations of IL-10 were estimated in 26 newly diagnosed patients with AML and follow up 19 of them after treatments, 7 patients were died after induction, matched 16 individuals' healthy donors. IL-10 levels were estimated using the enzyme‑linked immunosorbent assay (ELISA) technique. Patients were divided into two groups: 26 before treatment and 19 after treatment. The results showed that plasma concentrations of IL-10 were significantly higher in AML patients compared to control group. Moreover, plasma concentrations of IL-10 were significantly associated with non-responding (NR) AML patient after treatment compare to complete remission (CR). While it observed non-significantly before treatment. The study demonstrated that AML NR patients have increased plasma concentrations of IL‑10 after induction, suggesting that this cytokine is involved in the pathophysiological process of the disease and may be associated with poor prognosis of clinical outcomes.


Article
Cytokines profiling as prognostic markers in newly diagnosed acute myeloid leukemia

Authors: Hiba Shakir Ahmed --- Noor Thair Tahir --- Fatma Abdalhamza Obed
Journal: Iraq Joural of Hematology المجلة العراقية لامراض الدم ISSN: 20728069/25432702 Year: 2017 Volume: 6 Issue: 2 Pages: 65-68
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

BACKGROUND: Acute myeloid leukemia (AML) is a common acute leukemia in adult. Recent studieshave shown that cytokine systems influence leukemic cell biology and clinical investigations. Amongvarious cytokines, interleukin‑6 and interleukin‑10 (IL‑6 and IL‑10) participate an essential functionin progression of the disease.OBJECTIVE: The aim of this study is to quantify of IL‑6 and IL‑10 levels in AML patients who arenewly diagnosed and evaluate lipid profile to assess the relationship between lipid profile level andbody mass index (BMI) in myeloid leukemic patients.MATERIALS AND METHODS: Samples were collected from 45 patients with AML from AL‑YarmoukTeaching Hospital in addition to another 45 healthy individuals were served as a control group duringa period from October 2015 to October 2016. Patients ages ranged from 40 to 60 years. IL‑6 andIL‑10 were measured in all patients before any treatments and compared with control group.RESULTS: There was an increase in age, white blood cell, and hemoglobin in AML patients ascompared to control, but it was not significant. There was a significant increase in neutrophils andlymphocyte count, (P = 0.001). Furthermore, there was an increase in BMI, fasting blood sugar,and lipid profile except high‑density lipoprotein cholesterol for AML patients as compared to control,but it was not significant. There was a significant increase in serum IL‑6 and IL‑10 for AML patientscompared to controls (P = 0.001).CONCLUSIONS: The present study refers that AML patients were associated with high concentrationof IL‑6 and IL‑10 in comparing to the control group.


Article
Assessment of IL-6 Serum Level in Patients With Acute Myeloid Leukemia
تقييم معدل الانترلوكين 6 في مصول مرضى acute myeloid leukemia

Author: Sura Dhafir Dawood سرى ظافر داود
Journal: Iraqi Journal of Cancer and Medical Genetics المجلة العراقية للسرطان والوراثة الطبية ISSN: 20786123 Year: 2011 Volume: 4 Issue: 1 Pages: 22-28
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Background: Interleukin-6(IL-6) is a pleiotropic cytokine that plays a major role in response to injury orinfections and involved in immune response, inflammation and haematopoiesis. It is produced by a variety ofcell types in response to variety of stimulants. Also deregulation impacts to numerous disease states, includingmany types of cancer. Elevated IL-6 levels have been observed in most types of cancer and it’s implicated inthe pathogenesis of several disease such as acute myeloid leukemia, multiple myeloma, lymphoma and it maybe a prognostic factor for solid tumors, such as prostate cancer.Objectives: Estimation of the serum levels of IL-6 in patients with AML in different stages of the disease andassess their prognostic value and study its relationship with bacteremia, total leukocyte count ,and hemoglobinconcentration.Materials and Methods: Forty patients of AML in different stages in National centre of hematology-Baghdadwere studied immunologically for the detection of serum IL-6 by Enzyme Linked Immune SorbentAssay(ELISA) kit. Specimen of blood collected from AML in relapse stage with episode of fever, were subjectedto well known established microbiological methods for diagnosis and identification of isolates and datawere compared with 20 healthy donors.Results: Newly diagnosed and in relapse stage patients with AML had significantly higher serum levels ofIL-6 compared with both control group and leukemic patients in remission stage P<0.05,in addition there wasa positive correlation of IL-6 with the presence of fever due to bacterial infection .The clinical specimen resultin(8) isolates, from which (6) were coagulase negative and (2) were staphylococcus aureus ,all isolates showhigh sensitivity to erythromycin and high resistant to chloromphenicol .Also IL-6 level correlated positivelywith total leukocyte count (TLC) and inversely with hemoglobin (Hb) concentration in AML at diagnostic andrelapse stage.Conclusion: Serum levels of Interleukin-6 can be used as prognostic serum markers at diagnosis of adultsacute myeloid leukemia and it could be used as follow up parameters for early detection of relapse stage, inaddition it seem to be a good markers to detect patients with bacteremia.

تجابة المناعية والالتهابات وتكون أو تولد الدم .وينتج من قبل �� تجابة للإصابات والعدوى وكذلك في الاس �� ي في الاس �� المقدمة: يلعب الانترلوكين 6 دور أساسمختلف الخلايا نتيجة الاستجابة لمختلف المنبهات.بالإضافة إلى انه AML, Multiple myeloma, lymphoma رطانات وله تأثير في أمراضية أنواعا كثيرة منها �� ارتفاع معدل الانترلوكين 6 لوحظ في معظم السقد يلعب دور كعامل منبه لانواعا أخرى مثل سرطان البروستات.ة علاقته مع ارتفاع الحرارة �� في مراحله المختلفة من المرض وتقييم قيمته التنبوئية وكذلك دراس AML ر معدلات الانترلوكين 6 في مصول المرضى �� دف: تقدي


Article
Coagulopathy in Adult Acute Leukemia at Presentation in National Center of Hematology (NCH), Baghdad
تجلط الدم لدى المرضى البالغين المصابين بسرطان الدم الحاد في المركز الوطني لبحوث وعلاج امراض الدم / بغداد

Author: Abdulsalam Hatim Mohmmed د. عبد السلام حاتم محمد
Journal: IRAQI JOURNALOF COMMUNITY MEDICINE المجلة العراقية لطب المجتمع ISSN: 16845382 Year: 2013 Volume: 26 Issue: 2 Pages: 114-117
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

Abstract: Background: Malignancy is associated with a hypercoagulable state and a high risk for thrombohemorrhagic complications, clinical complications may range from localized thrombosis more in solid tumors to bleeding of varying degrees of severity because of disseminated intravascular coagulation (D.I.C.) as in acute leukemia. Aim of the study: To search for the real cause of coagulopathy (bleeding or thrombosis) in patients with acute leukemia.Materials and methods: This study was conducted at the NCH between January 2010 and September 2011, 96 patients with acute leukemia where evaluated prospectively for hemostatic abnormality at presentation of which 43 (44.79 %) had acute lymphoblastic leukemia (ALL) and 53 (55.21 %) had acute myeloid leukemia of which 14 (14.58) were cases of Acute Promyelocytic Leukemia (APL).Results: At presentation 2 patients (2.3 %) with AML (M3, APL) subtype had bleeding manifestation (signs of intracranial hemorrhage) and died with in 24-48 hours in spite of urgent supportive managements, (94)patients (97.9 %) had variable abnormalities of coagulation indices which include prothrombin time (P.T.) , partial thromboplastin time (P.T.T.), plasma fibrinogen level and Factor VII levels, ranging from normal indices specially in ALL to slight increment in AML mainly M2 to moderate increase in some patients with M3 (bleeding manifestations noticed to be associated more in few AML M3 this was attributed to the procoagulant activity of cytoplasmic granules in the malignant promyelocytes. Conclusion: From the results obtained in this study which shows that the cause of bleeding is mostly associated with low platelets count , but not due to coagulation factors defects (as only PT was increased in some cases of AML) .Key words: Acute lymphoblastic leukemia, acute myeloid leukemia, acute promyelocytic leukemia.

مابين كانون الثاني 2010 وايلول 2011 تم فحص (96) مريضاً يعانون من سرطان الدم الحاد حيث تم اجراء تقييم مستقبلي لحالات شذوذ تجلط الدم في المركز اعلاه منهم (43)مريضاً (44,79%)يعانون من سرطان الدم اللمفاوي الحاد (ALL) و (53)مريضاً (55,21%) يعانون من سرطان الدم النقياني الحاد (AML) منهم (14) مريضاً (14,58%) يعانون من سرطان السلانف النقويه الحاده (APL) . في هذه الدراسه مريضان (2,3%) من مرضى سرطان السلانف النقويه الحادة (APL) اظهرا علامات نزيف حاد (علامات نزيف داخل الجمجمة) وتوفيا في ظرف 24-48 ساعه على الرغم من اجراء المحاولات الداعمة العاجله .(94)مريضاً (97,9%) أظهروا شذوذ متغير من المؤشرات التي تشمل اوقات التخثر مثل وقت البروثرومبين (P.T)، وقت جزيئية الثرومبوبلاستين (P.T.T)، مستوى الفايبرينوجين في البلازما ومستوى العامل السابع في مصل الدم، يتراوح هذا الشذوذ بين المستويات الطبيعية في كل شيئ خصوصاً في مرضى سرطان الدم اللمفاوي الحاد الى زيادة طفيفه في مرضى سرطان الدم النقياني الحاد }خصوصاً النوع الثاني منه (AML/M2){ الى زيادة متوسطة خصوصاً في النوع الثالث }(APL)AML/M3 { وقد عزي ذلك الى فعالية الحبيبات السايتوبلازمه الموجودة في الخلايا السرطانية .


Article
RELATIONSHIP BETWEEN THE EXPRESSION OF CD34, CD123 AND MYELOPEROXIDASE MARKERS BY FLOW CYTOMETRY AND RESPONSE TO INDUCTION THERAPY IN ACUTE MYELOID LEUKEMIA

Authors: Faez Sh. Almohsen فائز شوقي عبد الصاحب المحسن --- Subh S. Al-Mudallal صبح سالم المدلل
Journal: IRAQI JOURNAL OF MEDICAL SCIENCES المجلة العراقية للعلوم الطبية ISSN: P16816579,E22244719 Year: 2014 Volume: 12 Issue: 2 Pages: 161-167
Publisher: Al-Nahrain University جامعة النهرين

Loading...
Loading...
Abstract

Background:Different immunophenotypic markers were found to be related to the prognosis of acute myeloid leukemia. Among them are CD34, CD123 and myeloperoxidase.Objective:To evaluate the relationship between the expression of CD34, CD123 and myeloperoxidase markers by flow cytometry; and the initial response to induction therapy in acute myeloid leukemia patients.Method:A cohort of forty one patients with newly diagnosed de novo acute myeloid leukemia were prospectively tested for the expression of CD34, CD123 and myeloperoxidase using multicolor flow cytometry and re-evaluated for the response to a 7+3 induction therapy regimen.Results:It was found that 64.29% of CD123- patients achieved complete remission while 70.37% of CD123+ patients not (P = 0.035). For CD34, 55.56% of CD34- patients achieved complete remission while 63.64% of CD34+ cases not. The induction failure in CD34+M3 cases was 100% (P = 0.045). Regarding myeloperoxidase, 61.54% of patients who had >20% myeloperoxidase expression achieved complete remission while 70.37% (myeloperoxidase expression in <20% of cells) failed to achieve complete remission (P = 0.05).Conclusion:Expression of CD34 and CD123 and weak expression of myeloperoxidase (<20% of blast cells) are associated with poor response to induction therapy in acute myeloid leukemia patients.Keywords:Flow cytometry, CD34, CD123, myeloperoxidase, acute myeloid leukemia


Article
IMMUNOLOGICAL PROFILE OF ACUTE MYELOID LEUKEMIA IN KURDISTAN IRAQ
الانماط المناعية لمرضى ابيضاض الدم النقوي الحاد في كوردستان- العراق

Authors: SANA DLAWAR JALAL سناء دلاور جلال --- BAYAR WASFY SALIM بيار وصفي سالم
Journal: Duhok Medical Journal مجلة دهوك الطبية ISSN: ISSN: 20717334 (online)/ ISSN: 20717326 (Print) Year: 2018 Volume: 12 Issue: 1 Pages: 1-12
Publisher: University of Dohuk جامعة دهوك

Loading...
Loading...
Abstract

ABSTRACTBackground: Immunophenotyping has become crucial in the diagnosis and classification ofacute leukemias and identification of its aberrant phenotypes. This study aimed to evaluatethe patterns in AML cases presented to the flowcytometry unit at the Sulaimani Public HealthLaboratory, Kurdistan, Iraq,and to determine the frequency of aberrant expression oflymphoid associated antigen.Subject and Methods: For the above purposes, 108 cases of acute myeloid leukemia (AML)were evaluated morphologically,and by flowcytometry with a panel of 22 antibodies.Furthermore, any aberrant expression of lymphoid associated antigens was reported.Results: The morphological AML subtyping revealed that 29.6% of AML cases were M2,while M1 (36.1%) was the predominant subtype by immunophenotyping using WHO 2008classification. CD117, CD45, CD13 and CD33 were the most frequently expressed markers(99.1%, 92.6%, 92.6% and 85.2% respectively). Forty-five patients (41.7%) expressedlymphoid associated antigens (nTdT, CD19, CD79a, CD10, CD4, CD56 and CD9) that wasdemonstrated in all AML subtypesexcept M6.CD56 was the most frequent(13%),followedby CD9 (12%), CD4 (8.3%), and CD19 (7.4%).CD79a, nTdT and CD10 were less frequent,present in <5% of cases each.Conclusions: Immunophenotyping is an essential supplement to morphology in AML,whether for confirmation or accurate subtyping. Furthermore, more than 40% of cases showaberrant lymphoid antigen expression. The latter may serve as an important tool in futurestudies on minimal residual disease evaluation.

الخلفية والأهداف دراسة النمط الظاهري المناعي "الاميونوفينوتايب" قد اصبح ضرورة في تشخيص وتصنيف إبيضاض الدم الحاد، ولا سيما من اجل التحديد الصحيح لأبيضاض الدم النقوي الحاد ذو التمايز الأرومي النقوي الأدنى AML M0)). إن الأنماط الشاذة للمعلمات السرطانية في أبيضاض الدم الحاد لا تزال مثار جدل من حيث نسب حدوثها و علاقاتهابإمكانية التنبؤ بمستقبل المرض. لذا كان الهدف من الدراسة هو لتقييم الانماط في حالات إبيضاض الدم النقوي الحاد التي قدمت الى وحدة الفلوسايتومتري في السليمانية/مختبر الصحة العامة/ كوردستان العراق، إضافة الى تحديد نسب حدوث الانماط الشاذة للمستضد اللمفاوي المرتبططرق البحث: للاغراض المذكورة اعلاه تم تقييم 108 من حالات إبيضاض الدم النقوي الحاد شكليا وفقا لتصنيف "FAB“وعن طريق تقنية الفلوسايتومتري مع مجموعةاجسام مضادة مكونة من 22 من جسم مضاد، مع الأخذ بنظر الإعتبار تحديد الانماط الشاذة للمستضد اللمفاوي المرتبط.النتائج: كشفت الدراسة أن إبيضاض الدم الحاد ذو نمو أرومي مكتمل (AML-M) تشكل 29% من إبيضاض الدم الحاد إعتمادا على تصنيف فاب، بينما إبيضاض الدم النقوي ذو الأرومات أولية التمايز(AML-M2) كان السائد 36.1% طبقا للتصنيف المعتمد من قبل منظمة الصحة العالمية لأورام الدم لسنة ٢٠٠٨م والتي تمت بوساطة تحديد المعلمات السرطانية بتقنية الفلوسايتومتري. فكانت المعلمات السرطانية CD117, CD45, CD13 and CD33 الأكثرظهورا بنِسَب(99.1%, 92.6%, 92.6% and 85.2%) على التوالي.اظهرت الدراسه وجود 45حالة تمتلك المعلمات السرطانية الشاذة للمستضد اللمفاوي المرتبط (41.7%) وقد وجدت في جميع الأنواع ماعدا إبيضاض الدم الحاد المتعلق بسلسلة كريات الدم الحمراء (AML –M6). CD56 كان الأكثر ترددا (13%)،ويليه CD9(12%) ثم CD4(8.3%) ويتبعه CD19 (7.4%),. في حين بقيه المعلمات السرطانية الشاذة للمستضد اللمفاويأقل ترددا بينها وبنسب ٥٪‏ لكل واحدة.الاستنتاجات: إن دراسة النمط الظاهري المناعي "الإميونوفينوتايب" ضروري لتحديد السلالة النقوية في إبيضاض الدم، ولكن لا يكفي وحده في تصنيف أنواع إبيضاض الدم النقوي الحاد طبقا لفاب. تتطلب دراسات اخرى تعتمد على الخصائص الوراثية الخلوية ومتابعة حالة المرضى سريريا لمعاينة أثر الأنواع المختلفة.


Article
Evaluation of CD96 and CD123 in CD34+ leukemic stem cells in acute myeloid leukemia patients and their relation to response to induction therapy

Authors: Raad Jaber Musa --- Haidar H. Al‑Fatlawi
Journal: Iraq Joural of Hematology المجلة العراقية لامراض الدم ISSN: 20728069/25432702 Year: 2016 Volume: 5 Issue: 2 Pages: 161-166
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

BACKGROUND: Leukemic stem cells (LSCs) are thought to originate either from normal hematopoietic stem cellsor from more differentiated progenitor cells. LSCs are capable of self‑renewal, proliferation, and differentiationinto malignant blasts.OBJECTIVE: To evaluate the expression of the LSC markers CD96 and CD123 in de novo acute myeloidleukemia (AML) patients, and to explore the relationship between those markers and response to inductiontherapy and prognostic factors in AML.MATERIALS AND METHODS: A cross‑sectional study was conducted on 30 adults with newly diagnosed AMLpatients were prospectively tested for the expression of CD96 and CD123 using four‑color flow cytometer at thetime of diagnosis and re‑evaluated at day 28 from the start of chemotherapy for the response to 3 + 7 inductiontherapy regimen.RESULTS: Eight cases (26.7%) expressed CD96, and 12 cases (40%) expressed CD123; all the CD96 positivecases were also CD123 positive, however, four cases among the CD123 positive patients did not express CD96.CD96 and CD123 were expressed more on blast cells in the cases of M5 French–American–British subtype,whereas the least expression was in M3. Among the eight cases with CD96+ expression, only (37.5%) acquiredCR, whereas cases without CD96 expression, (77.3%) acquired CR. Among the 12 cases with CD123+ expression,only (33.3%) acquired CR, while cases without CD123 expression, (88.9%) acquired CR.CONCLUSION: The expressions of CD96 and CD123 were associated with a higher total white blood cell countand bone marrow blast cells at presentation, and a lower response rate to the induction therapy.


Article
The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo acute myeloid leukemia

Authors: Wafaa Mohammed Al‑Anizi --- Mohammed Abdul Rassoul Al‑Mashta
Journal: Iraq Joural of Hematology المجلة العراقية لامراض الدم ISSN: 20728069/25432702 Year: 2017 Volume: 6 Issue: 2 Pages: 49-54
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

BACKGROUND: Immunophenotyping improves both accuracy and reproducibility of acute leukemiaclassification and is considered, particularly useful for identifying acute myeloid leukemia (AML) withlymphoid marker expression. The incidence of the aberrant phenotypes in AML is still controversial;incidences as high as 88% have been reported.OBJECTIVES: To evaluate the occurrence of aberrant lymphoid phenotypes and to correlate theirpresence with various French‑American‑British classification (FAB subtypes), 202 cases of newlydiagnosed AML were analyzed for lymphoid markers CD1a, CD2, CD3, CD4, CD5, CD7, CD8,CD10, CD19, CD20, and CD79a.MATERIALS AND METHODS: Whole blood or bone marrow aspirate of 202 patients with de novoAML was collected in ethylenediaminetetraacetic acid tube and analyzed by flow cytometry using alarge panel of fluorochrome‑labeled monoclonal antibodies. Identification of blast cells was performedusing forward scatter versus side scatter (SSC) parameters and CD45 intensity versus SSC dot plots.An antigen was considered positively expressed when at least 20% of the gated cells expressedthat antigen.RESULTS: Eighty‑five patients (42%) with de novo AML expressed lymphoid‑associated antigens.All AML subtypes demonstrated lymphoid‑associated antigens except M7. T‑cell aberrancy wasthe most common comprising 32.2% of the total aberrancy. The most frequently lymphoid antigenaberrantly expressed was CD7 (25.7%), followed by CD4 (22.4%) and CD19 (7.9%).CONCLUSION: A large number of AML cases showed aberrant lymphoid phenotypes. These lymphoidphenotypes might be associated with different leukemia subtypes. T‑cell markers are more commonthan B‑cell markers. CD7 was the most common lymphoid marker aberrantly expressed in AML.


Article
Evaluation of the expression of CD200 and CD56 in CD34‑positive adult acute myeloid leukemia and its effect on the response to induction of chemotherapy

Authors: Zainab Najah Muhsin --- Subh Salem Al‑Mudallal
Journal: Iraq Joural of Hematology المجلة العراقية لامراض الدم ISSN: 20728069/25432702 Year: 2018 Volume: 7 Issue: 1 Pages: 20-25
Publisher: Al-Mustansyriah University الجامعة المستنصرية

Loading...
Loading...
Abstract

BACKGROUND: Acute myeloid leukemia (AML) is characterized by an excess number of myeloidcells in the marrow with maturation arrest and infiltration of bone marrow (BM) and other tissues bymyeloblasts, resulting in BM failure.OBJECTIVES: The main goal of the present study is to investigate CD200 and CD56 aberrant expressionin CD34‑positive blasts, in newly diagnosed adult AML patients and their relation with the clinical andhematological parameters, as well as to identify their prognostic significance after induction therapy.MATERIALS AND METHODS: This was a prospective cross‑sectional study on thirty patients withnewly diagnosed AML, who were tested for the expression of CD200, CD56 using multicolor flowcytometry and re‑evaluated after induction therapy regimen.RESULTS: CD200 and CD56 were aberrantly expressed in 53.3% and 20.0%, respectively, whilecoexpression of both markers was observed in 13.3%. Interestingly, both markers were expressedmore in monocytic subtypes. Significantly, the induction failure in CD200 + patients was 75%, whileit was 66.7% in CD56+ patients.CONCLUSION: The findings of this research provide insights that CD200 and CD56 were closelyrelated to bad prognostic parameters, including high total white blood cell count, low platelet’s counts,and low response to induction therapy.

Listing 1 - 10 of 17 << page
of 2
>>
Sort by
Narrow your search

Resource type

article (17)


Language

English (14)

Arabic and English (2)


Year
From To Submit

2019 (1)

2018 (2)

2017 (2)

2016 (2)

2014 (2)

More...